Strategic Collaboration to Accelerate AAV-GAD Phase 3 Trials and Advance CNS Therapies

March 13, 2025 – MeiraGTx Holdings plc (Nasdaq: MGTX), a leader in genetic medicines, has announced a groundbreaking strategic collaboration with Hologen AI, a global pioneer in multi-modal AI for clinical medicine and drug development. This partnership is set to expedite the Phase 3 development of AAV-GAD—a promising gene therapy for Parkinson’s disease, while also leveraging AI-driven insights to transform the field of neurological drug discovery.

Key Highlights of the Collaboration

$200 Million Upfront Cash Investment – MeiraGTx secures immediate funding to support ongoing development.
Formation of Joint Venture: Hologen Neuro AI Ltd – Backed by $230 million in committed capital from Hologen AI, this venture will fully fund AAV-GAD development through commercialization.
Manufacturing and AI Integration – MeiraGTx’s proprietary AAV gene therapy manufacturing will be further optimized using Hologen AI’s generative models to enhance precision and efficiency.
Expanded Pipeline – The venture will also fund earlier-stage CNS therapies, including AAV-BDNF for genetic obesity.

AAV-GAD: A Game-Changer in Parkinson’s Treatment

AAV-GAD, MeiraGTx’s Phase 3-ready gene therapy, has already demonstrated significant clinical benefits in Parkinson’s patients. In a randomized, sham-controlled bridging study, AAV-GAD treatment resulted in:

18-point improvement in Unified Parkinson’s Disease Rating Scale (UPDRS) Part 3 at 26 weeks.
Significant quality of life improvements in the Parkinson’s Disease Questionnaire (PDQ-39).

This is now the second sham-controlled study showing a statistically significant improvement, reinforcing AAV-GAD’s potential as a disease-modifying therapy for Parkinson’s disease.

Neuro-AI: The Future of CNS Drug Discovery

This collaboration is more than just a funding agreement—it is a paradigm shift in how neurological disorders are studied and treated. By integrating Hologen’s AI foundation models, the joint venture aims to:

Enhance Trial Success Rates – AI-powered analysis of clinical data will improve trial design and patient selection.
Uncover Novel Biomarkers – Generative AI will help characterize disease mechanisms and track disease-modifying effects with unprecedented accuracy.
Optimize Manufacturing – AI-driven models will accelerate production and increase scalability for gene therapy manufacturing.

Leadership Perspectives

Alexandria Forbes, Ph.D., CEO of MeiraGTx:
“This collaboration transforms how we approach CNS drug development. Hologen’s AI has already de-risked our AAV-GAD program and illuminated the physiology of disease modification in Parkinson’s. Together, we’re creating a pioneering Neuro-AI clinical drug development platform with the potential to redefine treatment paradigms for neurodegenerative and neuropsychiatric disorders.”

What This Means for MeiraGTx

Immediate Capital Boost – $200M in cash strengthens MeiraGTx’s financial position, extending its runway while enabling further development of AAV-hAQP1 for xerostomia and Riboswitch technology for metabolic diseases and cell therapy.
AI-Driven Innovation – A first-of-its-kind Neuro-AI joint venture focused on transforming drug discovery and trial efficiency in the CNS space.
Long-Term Value Creation – MeiraGTx retains a 30% stake in the joint venture, maintaining substantial ownership in a fully funded late-stage drug development company.

Looking Ahead

This landmark partnership signifies the fusion of cutting-edge AI and genetic medicine, opening new avenues for breakthrough therapies in neurodegenerative diseases. With AAV-GAD entering Phase 3 trials and AI-powered insights guiding drug development, MeiraGTx and Hologen are set to reshape the future of precision neurology..

For more information, visit MeiraGTx and Hologen AI.